Novartis has inked a deal with China-based biotech Sironax that gives the pharma the exclusive option to acquire the ...

Kevin Tang's Concentra Biosciences lines up deal for flailing cancer cell therapy company Cargo Therapeutics — potentially ...

Hong Kong billionaire Richard Li’s insurer FWD Group saw its shares close flat in the company’s long-awaited Hong Kong stock ...

The digital health market is welcoming new IPOs for the first time in years. Bankers and investors think these 9 startups ...

In our new webinar series, Risk Management for Your Life Sciences Company, we discuss the insurance and risk management milestones life science companies should prepare for as they move from early ...

Baystreet.ca News Commentary – As populations age and chronic illnesses become more widespread, healthcare systems around the world are being pushed to their limits. But a ...

Initial public offerings (IPOs) just keep on coming in 2025 and they continue to remain in heavy demand. Companies have already raised about $25.4 billion through IPOs so far this year, exceeding the ...

Caris Life Sciences applies AI and machine learning to patient samples to detect cancer and as a companion diagnostic guiding the use of targeted cancer therapies. As a commercial-stage company ...

Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine. Click here to find out why CAI stock is a Hold.

Current Health Dynamics: Bird Flu Impact, Weight-Loss Innovations, and IPO Buzz Recent developments in health include Brazil's bird flu impacts harming its chicken exports, new weight-loss drugs ...

Despite raising the price of its IPO twice, Caris Life Sciences Inc. left money on the table with a 33% increase in price as soon as trading commenced on the Nasdaq, though no one is squawking about ...